{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:40:37Z","timestamp":1765438837505,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Samsung Bioepis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40744-022-00515-z","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T20:04:45Z","timestamp":1670529885000},"page":"329-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data"],"prefix":"10.1007","volume":"10","author":[{"given":"Wan-Hee","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Mo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Ha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon-Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Kyoung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Ha","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-0395","authenticated-orcid":false,"given":"Jung-Yoon","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"9","key":"515_CR1","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1517\/14656566.8.9.1373","volume":"8","author":"T Cobo-Ib\u00e1\u00f1ez","year":"2007","unstructured":"Cobo-Ib\u00e1\u00f1ez T, Mart\u00edn-Mola E. Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis. Expert Opin Pharmacother. 2007;8(9):1373\u201397.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"515_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2017.1347156","volume":"17","author":"X Guillot","year":"2017","unstructured":"Guillot X, et al. Etanercept for treating axial spondyloarthritis. Expert Opin Biol Ther. 2017;17(9):1173\u201381.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"515_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2019.1566456","volume":"19","author":"E Pelechas","year":"2019","unstructured":"Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"515_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"515_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/rheumatology\/kex269","volume":"56","author":"P Emery","year":"2017","unstructured":"Emery P, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology. 2017;56(12):2093\u2013101.","journal-title":"Rheumatology"},{"issue":"12","key":"515_CR6","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1136\/annrheumdis-2017-211591","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017;76(12):1986\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"515_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40744-019-00169-4","volume":"6","author":"HC Ebbers","year":"2019","unstructured":"Ebbers HC, et al. Real-world evidence on etanercept biosimilar SB4 in etanercept-na\u00efve or switching patients: a systematic review. Rheumatol Ther. 2019;6(3):317\u201338.","journal-title":"Rheumatol Ther"},{"key":"515_CR8","unstructured":"MFDS. Safety control after releasing medicinal products etc. Guideline on re-examination affairs of new drugs etc. (A guide for civil petitioner) Guide-0019-03. Jan-2019 [cited 2022 Jun-27]. Available from: https:\/\/www.mfds.go.kr\/eng\/brd\/m_18\/down.do?brd_id=eng0003&seq=71469&data_tp=A&file_seq=1."},{"issue":"4","key":"515_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, Van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin. 2009;35(4):745\u201357.","journal-title":"Rheum Dis Clin"},{"issue":"1","key":"515_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"515_CR11","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"6","key":"515_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","volume":"50","author":"CS Carlin","year":"2004","unstructured":"Carlin CS, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"515_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/art.11417","volume":"50","author":"DD Gladman","year":"2004","unstructured":"Gladman DD, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum. 2004;50(1):24\u201335.","journal-title":"Arthritis Rheum"},{"key":"515_CR14","unstructured":"MDfR, A. What\u2019s new: MedDRA version 22.0. 2019. Available from: https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/whatsnew_22_0_english.pdf."},{"key":"515_CR15","unstructured":"EMA. Benepali summary of product characteristics. [cited 2022 8-Jul]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benepali-epar-product-information_en.pdf."},{"issue":"3","key":"515_CR16","first-page":"74","volume":"3","author":"A La Noce","year":"2018","unstructured":"La Noce A, Ernst M. Switching from reference to biosimilar products: an overview of the European approach and real-world experience so far. EMJ. 2018;3(3):74\u201381.","journal-title":"EMJ"},{"issue":"2","key":"515_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001079","volume":"5","author":"U Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m U, et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics na\u00efve patients with spondyloarthritis. RMD Open. 2019;5(2): e001079.","journal-title":"RMD Open"},{"key":"515_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.55563\/clinexprheumatol\/usrd9z","volume":"39","author":"C Selmi","year":"2021","unstructured":"Selmi C, et al. BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis. Clin Exp Rheumatol. 2021;39:365\u201371.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"515_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/jcm11030621","volume":"11","author":"S Parisi","year":"2019","unstructured":"Parisi S, et al. Efficacy and drug survival after switching from etanercept to the biosimilar SB4: a real-life long-term study. J Clin Med. 2022;11(3):621. https:\/\/doi.org\/10.3390\/jcm11030621.","journal-title":"J Clin Med"},{"issue":"4","key":"515_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jbspin.2018.12.003","volume":"86","author":"V Sigurdardottir","year":"2019","unstructured":"Sigurdardottir V, Sv\u00e4rd A. Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months: a cohort study with historical controls. Jt Bone Spine. 2019;86(4):529\u201330.","journal-title":"Jt Bone Spine"},{"key":"515_CR21","doi-asserted-by":"publisher","first-page":"1759720X2096403","DOI":"10.1177\/1759720X20964031","volume":"12","author":"C Bruni","year":"2020","unstructured":"Bruni C, et al. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Ther Adv Musculoskelet Dis. 2020;12:1759720X20964031.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"515_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.917814","volume":"13","author":"E Allocati","year":"2022","unstructured":"Allocati E, et al. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13: 917814.","journal-title":"Front Pharmacol"},{"issue":"3","key":"515_CR23","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1111\/bjd.16032","volume":"178","author":"G Girolomoni","year":"2018","unstructured":"Girolomoni G, et al. Comparison of injection-site reactions between the etanercept biosimilar SB 4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. Br J Dermatol. 2018;178(3):e215\u20136.","journal-title":"Br J Dermatol"},{"issue":"1","key":"515_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJ van den Bemt","year":"2019","unstructured":"van den Bemt BJ, et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384\u201392.","journal-title":"Drug Deliv"},{"issue":"5","key":"515_CR25","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s12325-017-0523-x","volume":"34","author":"M Egeth","year":"2017","unstructured":"Egeth M, et al. Patient and healthcare professionals' preference for Brenzys vs. Enbrel autoinjector for rheumatoid arthritis: a randomized crossover simulated-use study. Adv Therapy. 2017;34(5):1157\u201372.","journal-title":"Adv Therapy"},{"issue":"1","key":"515_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-019-02765-3","volume":"76","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35\u201340.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00515-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00515-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00515-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:34:57Z","timestamp":1678685697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00515-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["515"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00515-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}